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Atrial ﬁbrillation (AF) is an arrhythmia associated with increased morbidity and mortality.
The pulmonary veins (PVs) play an important role not only in the onset but also the
maintenance of AF. Therefore, the goal of present AF ablation is to electrically disconnect the
PVs from the rest of the atrium by ablating around the origin of the PVs. Several groups using
ablation of all 4 PVs outside the tubular portion have reported that the success rate without
antiarrhythmic drugs is much more consistent, at 75 to 95%. A further 10% to 20% of patients
may become responsive to previously ineﬀective antiarrhythmic drugs. Although the success
rate of AF ablation appears high, a very low incidence of complications has been reported
including cardiac tamponade, embolism, esophageal injury, PV stenosis, and proarrhythmia
resulting from reentrant tachycardias. However, the complication rates can be decreased by
more recent modiﬁcations to the technique and presently available technologies. Thus, AF
ablation is an eﬀective, safe, and established treatment for AF that oﬀers an excellent chance
for a lasting cure.
(J Arrhythmia 2005; 21: 510–517)
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Atrial ﬁbrillation (AF) is a common and recurrent
rhythm disorder that aﬀects patient morbidity and
mortality. Catheter ablation for AF has emerged as a
promising new treatment strategy. In contrast to
antiarrhythmic drugs, catheter ablation directly elim-
inates the inciting factors for AF and oﬀers the
possibility of a lasting cure. Initially, various
methods for ablating AF have been tried. Creating
linear lesions in the atria mimicked the surgical
Maze procedure. However, after recognizing the
limited success and risks associated with this
approach, Haissaguerre et al.1) ﬁrst found that most
focal AF is initiated by premature beats from the
oriﬁces of the pulmonary veins (PVs) or from the
myocardial sleeves inside the PVs, and radiofre-
quency catheter ablation of triggered foci has been
shown to cure AF. However, detecting the exact
focus is often diﬃcult when atrial premature beats
are infrequent, or each extrasystole may induce AF,
thus necessitating repeated deﬁbrillation. For these
reasons, Haissaguerre et al.2) provided an alternative
approach that simply seeks to electrically isolate the
PVs from the left atrium (LA) at electrophysiolog-
ical breakthroughs from the LA to the PV.
Rationale of PV Isolation
In patients with chronic AF and structural heart
disease, after electrical cardioversion, the PVs are
also the dominant trigger reinitiating AF.3) There-
fore, the PVs may have an important role not only in
the onset but also the maintenance of AF.4) AF is
Address for correspondence: Koichiro Kumagai MD, Department of Cardiology, Fukuoka University Hospital, 7-45-1, Nanakuma, Jonan-
ku, Fukuoka 814-0180, Japan. Tel: 092-801-1011 Fax: 092-865-2692 E-mail: kxk@fukuoka-u.ac.jp
510
J Arrhythmia Vol 21 No 5 2005
Review Article
also perpetuated by microreentrant circuits, or rotors,
that exhibit high-frequency, periodic activity from
which spiral wave fronts of activation radiate into
surrounding atrial tissue.5,6) Conduction becomes
slower and less organized with increasing distance
from the rotors, likely because of atrial structural
remodeling, resulting in ﬁbrillatory conduction. The
dominant rotors in AF are localized primarily at the
PV–LA junction, as demonstrated by several inves-
tigators.6–8) Moreover, vagal inputs may be very
important in both triggering and maintaining AF, and
many of these inputs are clustered close to the PV–
LA junction.9) We also demonstrated that the PV–
LA junction has heterogeneous electrophysiological
properties capable of sustaining reentry.10) In our
study using a basket catheter mapping, unstable
reentrant circuits were observed in response to single
extrastimulus and repetitive focal activities in the
PV. When a coupling interval of extrastimulus or the
cycle lengths of repetitive focal activities are so
short, the rest of the PV cannot follow 1:1. The result
is that areas of functional block and slow conduction
are generated, which in turn serve to form unstable
reentrant circuit. However, these reentrant circuits
were short lived and never sustained for more than 2
rotations (i.e., were unstable). Furthermore, as shown
in the maps during initiation of AF (Figure 1), a PV–
LA reciprocating reentrant circuit involving the exit
breakthrough point and the entrance breakthrough
point at the PV–LA junction was observed. A wave
front from a focal discharge in the PV goes through
the nearest exit breakthrough point and re-enters to
the PV from the entrance site, forming a reentrant
circuit (Figure 2). The diﬀerent conduction property
of the exit and entrance sites depending on the site of
pacing or discharge may contribute to the reentry
formation. Wave fronts traveling to and from the LA
may play an important role in the formation of
unstable reentrant wave fronts. The presence of
anisotropic structures at the PV–LA junction may be
critical to form reentry.
Thus, the PVs play a critical role in both triggering
and maintaining AF. This was conﬁrmed with both
electrophysiological and histological data in an
open-heart, human model involving patients under-
going AF surgery.11) The mechanism also applies to
a wide spectrum of AF patients, including adoles-
cents12) and adults with structural heart disease.13,14)
Therefore, the goal of present AF ablation is to
electrically disconnect the PVs from the rest of the
atrium by ablating around the origin of the PVs.
Methodology of the Technique
It has been reported that >90% of PVs were
electrically disconnected from the LA by targeting
only certain segments of the ostial circumference, as
guided by PV potentials.2) The results conﬁrm that
there are isolated fascicles that travel from the LA
into the muscle sleeves surrounding the PVs and that
the ablation of these fascicles, as opposed to
circumferential ablation at the ostium, is suﬃcient
to isolate the PVs. In prior studies of segmental PV
isolation, only the PVs that were found to generate
triggers of AF were isolated.2) Recently, most
centers performing AF ablation are empirically
isolating all 4 PVs. It was recognized that any of
the PVs can serve as a trigger and that ablation of
only a single culprit PV may unmask triggers in
other PVs.15) Ablation of all 4 PVs was also found to
be more eﬀective than ablation of only 3.16) More-
over, most groups are ablating outside the tubular
portion of the PV to avoid the risk of PV stenosis and
to improve the eﬃcacy of the procedure. This makes
sense given that the PV is funnel shaped with a large
proximal end, which is called the antrum.17) The
antrum blends into the posterior wall of the LA, and
on the posterior wall. Therefore, to encompass as
much of the PV structure as possible, ablation needs
to be performed around the entire antrum, along the
posterior LA wall.17) Although diﬀerent groups may
refer to ablation in this region by diﬀerent names
such as LA catheter ablation, circumferential PV
antrum ablation, or extraostial isolation, the lesion
sets produced by the procedures are all very similar
(Figure 3).
In our own institution, we perform PV antrum
isolation using the double Lasso technique,18) that is,
two decapolar Lasso catheters (Biosense-Webster)
were placed within the ipsilateral superior and
inferior PVs during radiofrequency delivery. Abla-
tion of the PVs was performed as a pair. It was
performed 1 cm from the ostium of both right PVs
and for the posterior and superior aspects of the left
PVs to minimize the risk of PV stenosis. It was
started at the posterior wall and continued around the
venous perimeter. When ablation was required at the
anterior portions of the left PVs, energy had to be
delivered within the ﬁrst millimeters of the vein
(rather than the posterior wall of appendage) to
achieve eﬀective disconnection. Radiofrequency
energy was delivered for 30 seconds at each point;
this application was prolonged for 60 seconds when
a change in morphology or in the sequence of the PV
potentials occurred as determined by circumferential
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Figure 1 Analysis of consecutive activation patterns during a representative episode of spontaneous onset of AF.
Panel A: PV recordings from a basket catheter placed in the right superior PV during an episode of spontaneous onset of AF from F 5–6.
Numbers identify the conduction times from the earliest activation potential. Panel B: In this case, rapid repetitive ﬁrings induce the PV–
LA conduction block and a PV–LA reentrant circuit involving the exit breakthrough point (splines A–B) and the entrance breakthrough
point (spline F) is created. Also, a reentrant circuit lasting for 1.5 rotations with a cycle length of 100ms is observed within the PV.
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mapping. The procedural end point was total
elimination or dissociation of the PV potentials.
Radiofrequency energy was delivered with power
limited to 30 (inside) and 40W (outside the PV)
using 8mm-tip catheter. Temperature was limited to
50C. Inducibility of AF was assessed using burst
pacing. In the patients in whom AF was still present
or who still had inducible AF, additional linear
ablation at roof of the LA and/or mitral isthmus was
performed. Complete block was demonstrated by on
line mapping of double potentials and activation
mapping (Figure 4). Recently, Nademanee et al.19)
provided a new approach for AF ablation targeting
the electrophysiologic substrate for AF maintenance.
Therefore, in patients with persisting AF after PV
antrum isolation and linear ablation, we performed
additional ablation of the area with complex fractio-
nated electrograms.
PVLA
PV-LA juction
Figure 2 Schema of PV–LA junctional reentrant circuit.
PV = pulmonary vein potential, LA = left atrium.
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Figure 3 Radiofrequency lesions produced by various groups’ approaches to PV isolation.
Panel A, An outer view of LA of a patient in our institution as seen from the posterior aspect using 3D-CT. Black dotted lines represent the
anatomic locations of lesions. Panel B, Location of lesions produced using CARTO-guided approach described by Pappone and colleagues
(reproduced from Pappone et al35)). Panel C, Location of lesions produced with a CARTO-guided approach described by Morady and
colleagues (reproduced from Oral et al22)). Panel D, Location of lesions produced with a CARTO-guided approach described by Kuck and
colleagues (reproduced from Ouyang et al18)). In all cases, the location of the lesion sets is similar, encompassing the anterior and posterior
borders of all 4 PV antra.
LSPV = left superior PV; LIPV = left inferior PV; RSPV = right superior PV; and RIPV = right inferior PV.
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Eﬃcacy of AF Ablation
AF ablation has proved itself to be a very eﬀective
treatment for AF with operator experience, and
greater consistency in the technique, and with similar
success rates being reported by several diﬀerent
groups. According to the most recent reports from
several groups using ablation of all 4 PVs outside the
tubular portion, the success rate without antiarrhyth-
mic drugs is much more consistent, at 75 to 95%
(Table 1).18,20–24) A further 10% to 20% of patients
may become responsive to previously ineﬀective
antiarrhythmic drugs.25,26) Some variation remains,
partly because of variations in the precise end point
used and operator experience. Moreover, the cures
seem to be durable, given the long follow-up (almost
three years) reported by some groups20) and the
observation that most recurrences tend to occur early
in the follow-up period, and rarely occur very late
after ablation.27)
At our own institution, 91 patients with drug
refractory symptomatic AF (63 paroxysmal, 18
persistent, 10 permanent) underwent PV antrum
isolation. PV antrum isolation alone was performed
in 65 patients (49 paroxysmal, 12 persistent, 4
permanent). Linear ablation at the LA roof and/or
mitral isthmus was performed in 26 patients with
persisting or inducible sustained AF (14 paroxysmal,
6 persistent, 6 permanent). At 10 7 months, 80%
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Figure 4 PV antrum isolation and linear lesions.
Panel A, A ﬂuoroscopic view of LA of a patient in our institution as seen from the anterior-posterior aspect. White dotted lines represent
the anatomic locations of lesions. In the patients in whom AF was still present or who still had inducible AF after complete PV antrum
isolation, additional linear ablation at roof of the LA and/or mitral isthmus (MI) was performed. Complete block at LA roof was
demonstrated by on line mapping of double potentials (DP). Panel B, During distal coronary sinus (CS) pacing, ablation at the MI resulted
in a change of conduction sequence in the CS.
LSPV = left superior PV; LIPV = left inferior PV; RSPV = right superior PV; and RIPV = right inferior PV.
Table 1 Success rates of PV isolation in major centers.
Investigator Number of patients Ratio of paroximalAF (%) End Point
AF Free without
drugs (%)
Follow-Up
(day)
Haissaguerre et al21Þ 70 NA PVI 79 210
Pappone et al20Þ 589 69 EGM reduction 79 861
Oral et al22Þ 40 100 EGM reduction 88 365
Mansour23Þ 40 80 PVI 75 330
Marrouche et al24Þ 259 51 PVI 90 347
Ouyang et al18Þ 41 100 PVI 95 178
AF = atrial ﬁbrillation, PVI = pulmonary vein isolation, EGM = local electrogram amplitude.
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with PV antrum isolation alone (paroxysmal 84%,
persistent 75%, permanent 50%) and 85% with
additional ablation (paroxysmal 86%, persistent
83%, permanent 83%) were arrhythmia free without
antiarrhythmic drugs. One patient had cardiac
tamponade, 2 had LA ﬂutter. No PV stenosis was
observed. Thus, in our data, patients with parox-
ysmal and persistent AF may not require additional
linear LA ablation, whereas further ablation may be
necessary for patients with permanent AF. Further-
more, we performed the electro-guided atrial abla-
tion in 5 patients (3 persistent, 2 permanent) in
whom AF was still present or who still had inducible
AF despite after PV antrum isolation. In one patient
who had AF recurrence, all PVs had been completely
isolated on the second session, and the electro-
guided atrial ablation was therefore subsequently
performed. Radiofrequency ablation of the area with
complex fractionated electrograms was performed,
aiming to eliminate these electrograms. Complex
fractionated atrial electrograms were conﬁned to the
interatrial septum, roof of left atrium, coronary sinus,
and atrial appendage. During ablation of the areas
associated with fractionated electrograms, AF termi-
nated in 1 patient and AF converted to atrial
tachycardia in 3 patients. AF rendered noninducible
in 4 patients. During follow-up, 4 (80%) patients
were arrhythmia free (2 and 2 patients with and
without antiarrhythmic drugs, respectively). Thus,
when AF was still present or still had inducible AF
despite after PV antrum isolation, electro-guided
atrial ablation may be feasible and eﬀective as an
additional option.
Current evidence shows that AF ablation is not
only more eﬀective than pharmacological therapy
with such a high success rate and a low complication
rate but also may reduce both the morbidity and
mortality associated with medical therapy. Pappone
et al.20) reported that 589 patients who underwent AF
ablation had signiﬁcantly improved survival com-
pared with 582 matched patients who received
antiarrhythmic medications in a controlled, long-
term study (median follow-up, 900 days). Survival
among the patients who underwent AF ablation did
not diﬀer signiﬁcantly from the expected survival of
healthy, age- and gender-matched persons of the
Italian population. The total number of adverse
events, including stroke, were much less in the
ablated group, and freedom from AF in the ablated
group was signiﬁcantly higher than that in the
medical group (78% versus 37% in the ablated and
medical groups, respectively; P < 0:001). Other
investigators have also reported similar results in
head-to-head comparison,28) and other trials are
going on. Ablation may even be more cost-eﬀective
than medical therapy. Weerasooriya et al.29) demon-
strated that assuming a conservative ablation cure
rate of 72% after 1.5 procedures, the initially high
cost of ablation would oﬀset the ongoing costs of
antiarrhythmic drugs by 3 years; after 4 years,
ablation becomes more cost-eﬀective, and the
beneﬁt continues to increase thereafter. AF ablation
is clearly superior to our current standard therapy,
and with data showing greater eﬃcacy, less morbid-
ity and mortality, and even less cost.
Safety of AF Ablation
Although the success rate of AF ablation appears
high, a very low incidence of complications has been
reported. Complications accompanied with AF abla-
tion include vascular complications secondary to
venous access, cardiac perforation/tamponade, valv-
ular injury, embolic stroke or systemic embolism,
PV stenosis, esophageal injury, and proarrhythmia
resulting from reentrant tachycardias occurring from
incomplete ablative lesions. Finta et al.30) summa-
rized data from 63 clinical studies on AF ablation
encompassing 3339 patients between 1994 and 2003;
cerebrovascular events occurred in an average of
1.0% of patients, manifest PV stenosis in 0.9%, and
atrial macro reentry tachycardia in 29%. According
to only the more recent reports using a more
consistent ablation technique, the complication rates
are similar. However, the complication rates can be
decreased by more recent modiﬁcations to the
technique and presently available technologies. For
example, aiming for higher activated clotting times
of 300 to 400 seconds can reduce the incidence of
thromboembolism without increasing bleeding
risk,31) and ablation outside the tubular portion of
the PVs can minimize the risk of PV stenosis. Char
formation, tissue disruption, and esophageal injury
can also be avoided with strict limitations on
radiofrequency energy output32) and avoidance of
ablating directly on top of the esophagus. Natale’s
group has demonstrated that intracardiac echocar-
diography (ICE) is a useful and available tool to
minimize procedural complications and allows one
to perform safe transseptal access and avoid ablating
within the PVs to prevent stenosis by providing real-
time imaging.24) Additionally, tissue disruption and
coagulum formation causing stenosis and embolic
events can be minimized by titrating radiofrequency
energy output to prevent microbubble formation on
ICE.24) Procedure related atrial ﬂutters can also be
prevented by total electrical isolation of the PVs at
the level of the antra, thereby eliminating the triggers
Kumagai K Ablation for AF
515
for ﬂutter. Haissaguerre et al.21) have successfully
created additional LA linear lesions to avoid macro-
reentrant atrial tachycardias such as across the mitral
valve isthmus. New mapping and ablation systems to
improve the technique of ablation and reduce
complications are also imminent, including electro-
anatomic mapping integration, robotic/magnetic-
controlled catheter systems, balloon-guided systems,
and real-time 3D CT.
Indication of AF Ablation
Most previous studies have included only highly
symptomatic, paroxysmal or persistent AF patients
who have already failed pharmacological therapy,
with mild or moderate structural heart disease. These
patients show considerable morbidity and mortality
from AF, with exacerbation of heart failure, poor
exercise tolerance, and a major reduction in quality
of life. Ablation should be considered for patients
with symptomatic AF, mild to moderate structural
heart disease, and paroxysmal or persistent AF. In
such cases, AF should be recurrent and should not be
secondary to a transient, treatable cause. Ablation
may particularly beneﬁt younger patients with lone
AF who are frequently symptomatic and for whom
very long term antiarrhythmic and anticoagulation
therapy has higher risks and costs. Asymptomatic or
mild symptomatic AF patients may also beneﬁt from
ablation and sinus rhythm in the long term, but until
we get further clinical data, it is diﬃcult to justify an
invasive procedure to such patients.
It has been shown that good success of ablation
can be achieved in patients with left ventricular
dysfunction,13,33) previous cardiac surgery or valvu-
lar heart disease,14) and advanced age.34) In the
future, novel therapies to prevent or reverse the
promotion of structural remodeling may help make
AF more amenable to ablation. Another important
limitation of AF ablation is that it is being performed
only at a few select centers in most countries and is
not yet widely available. The beneﬁt of any new
invasive or surgical procedure highly depends on
operator skills. The present reality will gradually
develop, and advances such as robotically controlled
catheters and real-time MRI or CT imaging may
reduce operator experience aﬀecting the outcome of
ablation procedures.
Conclusions
AF is an arrhythmia associated with increased
morbidity and mortality. Current therapies, especial-
ly antiarrhythmic drugs, not only are ineﬀective but
also have a threat to patient quality of life and even
longevity. AF ablation is an eﬀective, safe, and
established treatment for AF that oﬀers an excellent
chance for a lasting cure. Unlike other therapies,
ablation tackles AF at its electrophysiological origin.
Therefore, it is about time that AF ablation could be
a ﬁrst-line therapy for selected patients with AF in
terms of eﬃcacy and safety.
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